Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Mutational inactivation and allelic loss of the von Hippel-Lindau (VHL) gene appear to be causal events for the majority of spontaneous clear-cell renal carcinomas. We now show that hypermethylation of a normally unmethylated CpG island in the 5' region provides another potentially important mechanism for inactivation of the VHL gene in a significant portion of these cancers. This hypermethylation was found in 5 of 26 (19%) tumors examined. Four of these had lost one copy of VHL while one retained two heavily methylated alleles. Four of the tumors with VHL hypermethylation had no detectable mutations, whereas one had a missense mutation in addition to hypermethylation of the single retained allele. As would be predicted for the consequence of methylation in this 5' CpG island, none of the 5 tumors expressed the VHL gene. In contrast, normal kidney and all tumors examined with inactivating VHL gene mutations but no CpG island methylation had expression. In a renal cell culture line, treatment with 5-aza-2'-deoxycytidine resulted in reexpression of the VHL gene. These findings suggest that aberrant methylation of CpG islands may participate in the tumor-suppressor gene inactivations which initiate or cause progression of common human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
Self-citationRole for DNA methylation in genomic imprinting
Li, E., Beard, C., & Jaenisch, R. (1993) · Nature · doi:10.1038/366362a0 · Cited by 1,964
Weinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,756
Hypomethylation of DNA from Benign and Malignant Human Colon Neoplasms
Goelz, S. E., Vogelstein, B., Hamilton, S. R., & Feinberg, A. P. (1985) · Science · doi:10.1126/science.2579435 · Cited by 840
High levels of De Novo methylation and altered chromatin structure at CpG islands in cell lines
Antequera, F., Boyes, J., & Bird, A. (1990) · Cell · doi:10.1016/0092-8674(90)90015-7 · Cited by 699
Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma
Zbar, B., Brauch, H., Talmadge, C., & Linehan, M. (1987) · Nature · doi:10.1038/327721a0 · Cited by 638
Self-citationSTOGER, R. (1993) · Cell · doi:10.1016/0092-8674(93)90160-r · Cited by 598
Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma
Greger, V., Passarge, E., H�pping, W., Messmer, E., & Horsthemke, B. (1989) · Human Genetics · doi:10.1007/bf00286709 · Cited by 574
Epigenetic mechanisms underlying the imprinting of the mouse H19 gene.
Bartolomei, M. S., Webber, A. L., Brunkow, M. E., & Tilghman, S. M. (1993) · Genes & Development · doi:10.1101/gad.7.9.1663 · Cited by 492
Cited by
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Self-citationNext-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
“All rights reserved©2013 Kyle Chang1, Nipun Kakkar1, Lisa R. Treviño1, Susan Benton1, Jeffrey G. Reid1, Donna Morton1, Harsha Doddapaneni1, Yi Han1, Lora Lewis1, Huyen Dinh1, Christie Kovar1, Yiming Zhu1, Jireh Santibanez1, Min Wang1, Walker Hale1, Divya Kalra1, Chad J. Creighton1,2, David A. Wheeler1, Richard A. Gib…”
BackgroundInfluentialGene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422
Self-citationThe history of cancer epigenetics
Feinberg, A. P., & Tycko, B. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1279 · Cited by 2,344
Motzer, R. J., Bander, N. H., & Nanus, D. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351207 · Cited by 2,219
Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., & Sidransky, D. (1995) · Nature Medicine · doi:10.1038/nm0795-686 · Cited by 1,986
Self-citationAlterations in DNA Methylation: A Fundamental Aspect of Neoplasia
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60702-2 · Cited by 1,928
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J.-P. J., Markowitz, S., Willson, J. K. V., Hamilton, S. R., Kinzler, K. W., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6870 · Cited by 1,887
Self-citationCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Self-citationThe epigenetic progenitor origin of human cancer
Feinberg, A. P., Ohlsson, R., & Henikoff, S. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1748 · Cited by 1,853
Biomarkers in Cancer Staging, Prognosis and Treatment Selection
Ludwig, J. A., & Weinstein, J. N. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1739 · Cited by 1,666
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
DNA hypermethylation in tumorigenesis: epigenetics joins genetics
Baylin, S. B., & Herman, J. G. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01971-x · Cited by 1,628
Self-citationRini, B. I., Campbell, S. C., & Escudier, B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,621
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
Self-citationIdentification and Characterization of a Family of Mammalian Methyl-CpG Binding Proteins
Hendrich, B., & Bird, A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.11.6538 · Cited by 1,360
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future
Esteller, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205600 · Cited by 1,233
Integrated molecular analysis of clear-cell renal cell carcinoma
Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato-Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,221
Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,208
DNA methylation and gene silencing in cancer
Baylin, S. B. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0354 · Cited by 1,154
Role of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 943
HIF-1 and human disease: one highly involved factor
Semenza, G. L. (2000) · Genes & Development · doi:10.1101/gad.14.16.1983 · Cited by 909
“The key genetic lesion in hemangioblastoma and in clear cell renal carcinoma, another extensively vascularized tumor type, is functional inactivation of the von Hippel-Lindau (VHL) tumor suppressor (Gnarra et al. 1994; Herman et al. 1994; Kanno et al. 1994; Shuin et al. 1994).”
BackgroundRini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S.-S., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9847 · Cited by 899
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., & Goldberg, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10595 · Cited by 892
Molecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
DNA methylation: a historical perspective
Mattei, A. L., Bailly, N., & Meissner, A. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.03.010 · Cited by 861
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
Stebbins, C. E., Kaelin, W. G., & Pavletich, N. P. (1999) · Science · doi:10.1126/science.284.5413.455 · Cited by 860
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours
Esteller, M., & Herman, J. G. (2002) · The Journal of Pathology · doi:10.1002/path.1024 · Cited by 743
Self-citationDNA methylation, methyltransferases, and cancer
Robertson, K. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204341 · Cited by 736
Epigenetics and colorectal cancer
Lao, V. V., & Grady, W. M. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.173 · Cited by 736
The colorectal adenoma–carcinoma sequence
Leslie, A., Carey, F. A., Pratt, N. R., & Steele, R. J. C. (2002) · British Journal of Surgery · doi:10.1046/j.1365-2168.2002.02120.x · Cited by 734
Epigenetic gene silencing in cancer: the DNA hypermethylome
Esteller, M. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm018 · Cited by 725
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731
Yoshikawa, H., Matsubara, K., Qian, G.-S., Jackson, P., Groopman, J. D., Manning, J. E., Harris, C. C., & Herman, J. G. (2001) · Nature Genetics · doi:10.1038/ng0501-29 · Cited by 722
Self-citationTargeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature · doi:10.1038/nature19796 · Cited by 709
Tumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A., Gray, S., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 703
Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
Kibel, A., Iliopoulos, O., DeCaprio, J. A., & Kaelin, W. G. (1995) · Science · doi:10.1126/science.7660130 · Cited by 671
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
Semenza, G. L. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169186 · Cited by 654
Veigl, M. L., Kasturi, L., Olechnowicz, J., Ma, A., Lutterbaugh, J. D., Periyasamy, S., Li, G.-M., Drummond, J., Modrich, P. L., Sedwick, W. D., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8698 · Cited by 648
Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas.
Yoshiura, K., Kanai, Y., Ochiai, A., Shimoyama, Y., Sugimura, T., & Hirohashi, S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7416 · Cited by 645
Wu, J., Jiao, Y., Dal Molin, M., Maitra, A., de Wilde, R. F., Wood, L. D., Eshleman, J. R., Goggins, M. G., Wolfgang, C. L., Canto, M. I., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118046108 · Cited by 640
Whang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. W., Isaacs, W. B., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5246 · Cited by 639
DNA Methylation Clocks in Aging: Categories, Causes, and Consequences
Field, A. E., Robertson, N. A., Wang, T., Havas, A., Ideker, T., & Adams, P. D. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.008 · Cited by 621
The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
Linehan, W. M., & Ricketts, C. J. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0211-5 · Cited by 621
Self-citationDNA methylation: past, present and future directions
Robertson, K. D., & A.Jones, P. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.461 · Cited by 607
ABERRANT DNA METHYLATION AS A CANCER-INDUCING MECHANISM
Esteller, M. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095832 · Cited by 549
Inhibition of DNA Methylation and Reactivation of Silenced Genes by Zebularine
Cheng, J. C., Matsen, C. B., Gonzales, F. A., Ye, W., Greer, S., Marquez, V. E., Jones, P. A., & Selker, E. U. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.399 · Cited by 535
Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassiliou, E., Oldfield, E. H., Klausner, R. D., & Linehan, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10589 · Cited by 531
Self-citationMaher, E. R., & Kaelin, W. G. (1997) · Medicine · doi:10.1097/00005792-199711000-00001 · Cited by 528
HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma
Gordan, J. D., Lal, P., Dondeti, V. R., Letrero, R., Parekh, K. N., Oquendo, C. E., Greenberg, R. A., Flaherty, K. T., Rathmell, W. K., Keith, B., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.016 · Cited by 493
“Methylation studies were performed using the CpG Wiz Kit (Chemicon, Inc) and/or Not1 digestion (Herman et al., 1994).”
MethodLund, A. H., & van Lohuizen, M. (2004) · Genes & Development · doi:10.1101/gad.1232504 · Cited by 489
Cairns, P. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0176 · Cited by 485
Post, W. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00153-4 · Cited by 482
THE ROLE OF DNA METHYLATION IN CANCER GENETICS AND EPIGENETICS
Laird, P. W., & Jaenisch, R. (1996) · Annual Review of Genetics · doi:10.1146/annurev.genet.30.1.441 · Cited by 472
p16(MTS-1/CDKN2/INK4a) in Cancer Progression
Rocco, J. W., & Sidransky, D. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5149 · Cited by 470
Epigenetic memory at embryonic enhancers identified in DNA methylation maps from adult mouse tissues
Hon, G. C., Rajagopal, N., Shen, Y., McCleary, D. F., Yue, F., Dang, M. D., & Ren, B. (2013) · Nature Genetics · doi:10.1038/ng.2746 · Cited by 467
Targeted Therapy for Metastatic Renal Cell Carcinoma
Motzer, R. J., & Bukowski, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5415 · Cited by 454
Cross, S. H., & Bird, A. P. (1995) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(95)80044-1 · Cited by 450
Costello, J. F., & Plass, C. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.5.285 · Cited by 442
Mizuno, S.-I., Chijiwa, T., Okamura, T., Akashi, K., Fukumaki, Y., Niho, Y., & Sasaki, H. (2001) · Blood · doi:10.1182/blood.v97.5.1172 · Cited by 438
Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., & Klausner, R. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00044-2 · Cited by 432
Self-citationVascular tumors in livers with targeted inactivation of the von Hippel–Lindau tumor suppressor
Haase, V. H., Glickman, J. N., Socolovsky, M., & Jaenisch, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1583 · Cited by 424
p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3
Wales, M. M., Biel, M. A., Deiry, W. E., Nelkin, B. D., Issa, J.-P., Cavenee, W. K., Kuerbitz, S. J., & Baylin, S. B. (1995) · Nature Medicine · doi:10.1038/nm0695-570 · Cited by 421
Metabolic control of epigenetics in cancer
Kinnaird, A., Zhao, S., Wellen, K. E., & Michelakis, E. D. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.82 · Cited by 420
The cancer epigenome—components and functional correlates
Ting, A. H., McGarvey, K. M., & Baylin, S. B. (2006) · Genes & Development · doi:10.1101/gad.1464906 · Cited by 419
Somatic mutation of the MEN1 gene in parathyroid tumours
Heppner, C., Kester, M. B., Agarwal, S. K., Debelenko, L. V., Emmert-Buck, M. R., Guru, S. C., Manickam, P., Olufemi, S.-E., Skarulis, M. C., Doppman, J. L., et al. (1997) · Nature Genetics · doi:10.1038/ng0897-375 · Cited by 415
Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications
Santini, V., Kantarjian, H. M., & Issa, J.-P. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-7-200104030-00011 · Cited by 414
Regulation of Angiogenesis by Oxygen and Metabolism
Fraisl, P., Mazzone, M., Schmidt, T., & Carmeliet, P. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.003 · Cited by 413
Rini, B. I., & Small, E. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.186 · Cited by 408
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer
Schödel, J., Grampp, S., Maher, E. R., Moch, H., Ratcliffe, P. J., Russo, P., & Mole, D. R. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.007 · Cited by 405
Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., & Plate, K. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203938 · Cited by 396
“VHL inactivation due to gene silencing is a common phenomenon, since hypermethylation of CpG islands in the 5' region leading to inactivation of the VHL gene was reported in 19 per cent of spontaneous renal clear cell carcinomas (Herman et al., 1994).”
BackgroundThe role of enhancers in cancer
Sur, I., & Taipale, J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.62 · Cited by 389
Age-associated DNA methylation in pediatric populations
Alisch, R. S., Barwick, B. G., Chopra, P., Myrick, L. K., Satten, G. A., Conneely, K. N., & Warren, S. T. (2012) · Genome Research · doi:10.1101/gr.125187.111 · Cited by 389
Momparler, R. L., & Bovenzi, V. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200005)183:2<145::aid-jcp1>3.0.co;2-v · Cited by 387
Lonergan, K. M., Iliopoulos, O., Ohh, M., Kamura, T., Conaway, R. C., Conaway, J. W., & Kaelin, W. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.732 · Cited by 381
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer
He, B., You, L., Uematsu, K., Zang, K., Xu, Z., Lee, A. Y., Costello, J. F., McCormick, F., & Jablons, D. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2232790100 · Cited by 380
Rini, B. I., Campbell, S. C., & Rathmell, W. K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000219260.60714.c4 · Cited by 379
Clifford, S. C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1029 · Cited by 373
Lee, Y.-W., Klein, C. B., Kargacin, B., Salnikow, K., Kitahara, J., Dowjat, K., Zhitkovich, A., Christie, N. T., & Costa, M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2547 · Cited by 367
Hawkins, N., Norrie, M., Cheong, K., Mokany, E., Ku, S., Meagher, A., O'Connor, T., & Ward, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.32997 · Cited by 366
GRØNBÆK, K., HOTHER, C., & JONES, P. A. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_636.xml.x · Cited by 366
Singal, R., & Ginder, G. D. (1999) · Blood · doi:10.1182/blood.v93.12.4059 · Cited by 365
Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors
Saghafinia, S., Mina, M., Riggi, N., Hanahan, D., & Ciriello, G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.082 · Cited by 357
Driver and Passenger Mutations in Cancer
Pon, J. R., & Marra, M. A. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040312 · Cited by 355
Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas
Welander, J., Söderkvist, P., & Gimm, O. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0170 · Cited by 355
Catteau, A., Harris, W. H., Xu, C.-F., & Solomon, E. (1999) · Oncogene · doi:10.1038/sj.onc.1202509 · Cited by 354
Patel, N. S., Li, J.-L., Generali, D., Poulsom, R., Cranston, D. W., & Harris, A. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1208 · Cited by 349
“CC-RCC, the most common type of malignant renal tumor, accounting for 70% to 80% of cases (30), occurs in both a hereditary and sporadic form, both of which are associated with mutations in the von Hippel-Lindau (VHL) gene (31, 32).”
BackgroundComparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer
Schuebel, K. E., Chen, W., Cope, L., Glöckner, S. C., Suzuki, H., Yi, J.-M., Chan, T. A., Neste, L. V., Criekinge, W. V., Bosch, S. V. D., et al. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030157 · Cited by 347
Self-citationHypermethylation of the DAP-Kinase CpG Island Is a Common Alteration in B-Cell Malignancies
Katzenellenbogen, R. A., Baylin, S. B., & Herman, J. G. (1999) · Blood · doi:10.1182/blood.v93.12.4347 · Cited by 345
Self-citationYamashita, K., Upadhyay, S., Osada, M., Hoque, M. O., Xiao, Y., Mori, M., Sato, F., Meltzer, S. J., & Sidransky, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00215-5 · Cited by 340
The epigenetics of cancer etiology
Feinberg, A. P. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.005 · Cited by 337
Kaelin, W. G. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.092049 · Cited by 336
Deletions of the Short Arm of Chromosome 3 in Solid Tumors and the Search for Suppressor Genes
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60096-2 · Cited by 335
Brannon, A. R., Reddy, A., Seiler, M., Arreola, A., Moore, D. T., Pruthi, R. S., Wallen, E. M., Nielsen, M. E., Liu, H., Nathanson, K. L., et al. (2010) · Genes & Cancer · doi:10.1177/1947601909359929 · Cited by 331
Epigenetic drivers of tumourigenesis and cancer metastasis
Chatterjee, A., Rodger, E. J., & Eccles, M. R. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.004 · Cited by 328
Metadata
- Authors
- Herman, J. G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., Samid, D., Duan, D. S., Gnarra, J. R., & Linehan, W. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-10-11
- Volume
- 91
- Issue
- 21
- Pages
- 9700-9704
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2150162153
- Cited by
- 1,529
- References
- 29
- FWCI
- 17.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.